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Dear Sir, 
the management of ulcerative colitis (UC) typically requires lifelong pharmacological 
therapy to induce and maintain remission; the first-line therapy for mild or moderate 
UC is represented by the drug 5-aminosalicylic acid (5-ASA) [1]. 
In an interesting study, evaluating the general rate of compliance with mesalazine in 
UC patients, 198 outpatients > 18 years old treated at the Gastroenterology and 
Hepatology departments of three medical centres across the Czech Republic were 
included. Adherence was assessed by subjecting patients to a questionnaire. The 
authors found non-compliance (usage of less than 80% of medications) with 5-ASA 
in 21.2% of these patients. Gender (p=.95), duration of treatment (p=.58), number of 
doses per day (p=.38), pharmaceutical form (i.e., small tablets/large tablets/sachets 
plus rectal form/combinations) (p=.7) were not found to influence the compliance. On 
the contrary, a significant difference (p=.01) was found between the compliance of 
patients with secondary school diploma (84.1 ± 16.73) and those with university 
diploma (94.1 ± 9.9) [2].  
Recently, we performed a blind prospective study in which the adherence to the 
treatment with mesalazine, in inflammatory bowel disease (IBD) patients. The 
patients underwent to an anonymous questionnaire to be completed alone at the 
time of the visit, with questions regarding the patient (sex, age, education level, 
comorbidity, drugs taken for other illnesses), the disease (type of IBD, years after the 
diagnosis, the time elapsed from the onset of the symptoms to the definitive 
diagnosis) and the therapy (type of therapy taken, the number of missed doses in the 
last 2 weeks, the concern for side effects, the decision to skip doses when they feel 
better, alternative therapies). Three hundred seventy-six patients were included, of 
which 221 Crohn’s disease (CD) patients. Among 147 UC patients, the adherence 
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(the patients reported to have never missed a single dose of 5-ASA in the last 2 
weeks) resulted 60.6%. The adherence to the therapy among all female patients was 
lower than among male patients in the whole IBD population (p=.015) but, similarly to 
the above reported study [2], in the group of UC patients the difference was not 
statistically significant (p=.6). Even in our study, neither the number of drugs for IBD 
(p=.1) nor the number of medications for other illnesses influenced the adherence to 
the therapy (p>.47). Instead, in our population the school diploma did not influence 
the adherence (t-test for trend p>.38). A finding that deserves attention was that in 
our patients with UC, the adherence was significantly lower among those with a 
disease duration between 2 and 5 years compared to patients with a disease 
duration of <2 years (p=.04) (while the adherence increases again in patients with a 
disease duration >5 years) [3]. In the article by Keil et al., the comparison was only 
between patients with disease duration < or >5 years [2]. Our finding probably 
reflects the fact that, even if in our study a statistically significant correlation between 
the disease’ activity at the time of evaluation and the adherence was not found, in 
patients with UC the start of the therapy at the time of the diagnosis determines a 
rapid symptomatic amelioration (especially of the ematochezia, a symptom that 
greatly worries the patient), inducing in the patient the wrong thought to be ‘cured’ 
and therefore causing less attention to the therapeutic regimen. Subsequently, due 
to the likely recurrence of the symptomatology in case of poor adherence to the 
therapy, the compliance increases again and will not decrease significantly anymore. 
Hence, the initial period requires, from a gastroenterologist’s point of view, more 
attention and probably more consultations to stimulate the rigorous application of the 
therapeutic plan. Furthermore, for the first time in the literature, we found a 
statistically significant difference (p=.001), at least in patients with CD, in terms of 
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compliance, between those who underwent or not to surgical resection. Hence, after 
the experience of an invasive treatment, the compliance to medical therapy 
improved.  
In conclusion, our findings agree with those of Keil et al., with the demonstration that 
the factors influencing the adherence to the therapy are only partly related to the 
prescribed therapy. A deepening on the adherence to therapy in the early years of 
UC diagnosis (in particular between 2 and 5 years from the diagnosis), and on the 
role of previous surgical resection in patients with CD is mandatory. This could give 
to the clinicians weapons to be exploited in the doctor-patient relationship to improve 
the adherence to the therapy and, in turn, to reduce both the risk of complications 
related to the disease and the health care costs. 
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